Changchun Changsheng Life goes under after tainted vaccine scandal

Chinese vaccine maker, Changchun Changsheng Life Sciences, involved in a defective vaccine case, was handed a bankruptcy ruling by a court in northeast China, according to an announcement today by the Shenzhen Stock Exchange, Xinhua reports.

The Intermediate People’s Court of Changchun, capital of Jilin province, ruled that Changchun Changsheng is insolvent and unable to pay its debts when they are due. Meanwhile, there is no possibility of reorganization, the announcement said.

Changchun Changsheng Life Sciences is a subsidiary of Changsheng Bio-technology, a major Chinese vaccine maker.

Last year, authorities revoked their pharmaceutical production license and imposed a fine of more than 9.1 billion yuan on Changchun Changsheng for illegal production of vaccines.In July 2018, Shenzhen-listed Changsheng Biotechnology, made a public apology and voluntarily recalled all its rabies vaccines available on the market, state media reported at the time. The company said the recall would cost over 200 million yuan, CGTN reported.

In 2017, a batch of the vaccines immunizing children against whooping cough, diphtheria and tetanus had failed to conform to standards for biological potency.

Source: Changchun Changsheng Life goes under after tainted vaccine scandal

One thought on “Changchun Changsheng Life goes under after tainted vaccine scandal

  • February 26, 2020 at 9:43 pm

    Given the propensity of vaccine manufacturers in China to get caught not caring about vaccine safety in the interests of making a profit, lets look at the scale of Chinas vaccine production.

    Between 2007 and 2015, the annual supply of vaccines in China ranged between [b]666 million and 1,190 million doses[/b], with [b]most doses produced domestically. The government’s Expanded Program on Immunization (EPI) prevents 12 vaccine preventable diseases (VPD) through routine immunization. China produces vaccines that are in common use globally; however, the number of routinely-prevented diseases is fewer than in high- and middle-income countries.


    Enter the WHO (circa 2014)

    China enters the global vaccine marketChina is gearing up to supply the world with affordable vaccines that fulfil all efficacy, safety and quality requirements. 
    When WHO pre-qualified a Chinese-made vaccine for the first time last October, the move showed what Chinese vaccine manufacturers could potentially achieve and – in a sense – paved the way for others to follow suit.
    In July, this status was renewed, after a successful WHO reassessment of the vaccine regulatory part of the CNRA. WHO Director-General Dr Margaret Chan welcomed the news saying: “As a result of this evaluation, WHO is confident in the quality, safety and effectiveness of vaccines that are made in China.”

    Hmmmmm….in 2014 WHO greenlighted China

Comments are closed.
Translate »